Selecta is working on two antigen-specific SVP™ platforms covering immune tolerance and immuno-stimulatory vaccines.
Targeted tolerogenic Synthetic Vaccine Particles (t2SVP™) are designed to induce antigen-specific immune tolerance. Selecta researchers are working on applications in autoimmune diseases, allergies, as well as the inhibition of drug induced immune reactions such as anti-drug antibodies (ADA), anaphylaxis and injection site reactions.
Targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles target humoral and cellular pathways of the immune system inducing robust antibody and cytolytic T cell responses. Selecta's pipeline includes a prophylactic vaccine for malaria and therapeutic vaccines in cancer, chronic infections and addiction.